Orforglipron
Also known as: LY3502970, OWL833
Molecular Identifiers
Overview
Non-peptide oral GLP-1 receptor agonist, with a molecular weight of approximately 541.6 Da. Represents a new class of small molecule GLP-1 agonists administered orally, overcoming the bioavailability limitations of peptide analogs. In advanced clinical development for type 2 diabetes and obesity.
In phase 3 clinical trials for type 2 diabetes and obesity, developed by Eli Lilly. First non-peptide oral GLP-1 agonist with promising results of up to 14.7% weight loss in phase 2.
Small molecule — non-peptide oral GLP-1 receptor agonist
Half-life
~29-49 hours
Administration Route
Oral
Category
Metabolic & Fat Loss
Mechanism of Action
- GLP-1 receptor agonism as a non-peptide oral small molecule
- Stimulation of glucose-dependent insulin secretion
- Suppression of postprandial glucagon secretion
- Reduction of appetite and caloric intake via central signaling
- Delayed gastric emptying
- Improved insulin sensitivity in peripheral tissues
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 12-36 mg per day (oral) |
| Frequency | Once daily |
| Timing | Morning, with or without food |
| Duration | Continuous use (with gradual dose escalation) |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Nausea
- Vomiting
- Diarrhea
- Decreased appetite
- Constipation
Presentations & Preparation
Vials of Orforglipron found in the research market:
Reconstitution
- Diluent: Not applicable — oral tablet formulation
- Volume: Not applicable
- Administer the whole tablet with water
- Do not crush, chew, or split the tablet
- Gradual dose escalation according to tolerability
Storage
- Lyophilized: Controlled room temperature (15-30°C)
- Reconstituted: Not applicable
- Protect from moisture
- Keep in original packaging
- Does not require refrigeration
Scientific Studies
Published studies on Orforglipron.
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
Frias JP, Hsia S, Engel SS, Khanna S, Dunbar SA, Nedelcu L, et al.
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al.
Related Peptides
5-Amino-1MQ
50 mg per capsule · 1-2 times daily
Adipotide
0.5-1 mg/kg per injection (subcutaneous) · Once daily
AICAR
50-150 mg per injection · 2-3 times per week
AOD 9604
300-600 mcg per injection · Once daily
Cagrilintide
1.2-4.5 mg per week (subcutaneous) · Once weekly
Dulaglutide
0.75-4.5 mg per week (subcutaneous) · Once weekly